Menu
Back to Journals » International Journal of Women's Health » Volume 5
Update on first-line treatment of advanced ovarian carcinoma
Authors Kemp Z, Ledermann JA
Received 14 November 2012
Accepted for publication 14 December 2012
Published 25 January 2013 Volume 2013:5 Pages 45—51
DOI https://doi.org/10.2147/IJWH.S30231
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Z Kemp,1 JA Ledermann1,2
1Department of Oncology, University College London Hospitals, 2University College London Cancer Institute, University College London, London, United Kingdom
Abstract: Despite the high response rate to first-line treatment of advanced ovarian cancer, the vast majority of patients relapse. Maximal debulking surgery and chemotherapy with a platinum doublet have remained the standard of care for many years and new approaches are imperative. Recent clinical trials have given grounds for hope. Neoadjuvant chemotherapy, intraperitoneal delivery, and dose-dense strategies have all shown promising results, as has the targeting of angiogenesis. A greater understanding of the molecular landscape of ovarian cancer is helping to identify new treatment options. In this review, we will highlight the key trials and recent progress in these areas.
Keywords: ovarian cancer, first-line therapy, neoadjuvant, intraperitoneal, dose-dense, angiogenesis
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.